Contents

Dr Mark Bunnage, senior vice president and head of Global Research at Vertex, talks to Pharmafocus about scientific innovation to help create transformative medicines for people living with serious diseases.

This section contains the latest news regarding clinical trials, starting with news from Aravax regarding successful recruitment for its peanut allergy trial.

This section contains a roundup of some of the latest approvals, including a new drug for the treatment of breast cancer from Novartis.

News of the latest research is explored here, with news about an automation lab in China from SPT Labtech and ICE Bioscience.

One of the most recent acquisitions is of Phenocell, by Axol Bioscience.

Move of the month Dr Souad Kechairi has been appointed as chief medical officer at PLL Therapeutics.

Our Team

Executive Director
PMGroup Worldwide Ltd
Karl Equi

Group Managing Editor
Iona Everson

Deputy Editor
Natalia Elliot
natalia@samedanltd.com

James Spargo
james@samedanltd.com

Business Manager
Louise Wilson-English
louise@samedanltd.com

Design & Layout
Peter May

Pharmafocus is published by:

Samedan Ltd
44 Maiden Lane, London
WC2E 7LN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747

Subscriptions & Data Management

Curwood CMS Tel: 01580 883840

ISSN: 1465-5403

Pharmafocus is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).

All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.

©2024 Samedan Ltd, Pharmaceutical Publishers

The opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.